Concepedia

mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization

Hippocrates Moschouris, Katerina Malagari, Marina Papadaki, Ioannis Kornezos, Konstantinos Stamatiou, Katerina Chatzimichael, Nikolaos Kelekis

Diagnostic and Interventional Radiology · 2013 · 21 citations · 22 references

DOIFull text

Open access

Abstract

The mRECIST-CEUS combination is feasible and has prognostic value in the assessment of hepatocellular carcinoma following transarterial chemoembolization.

References

22

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Management of Hepatocellular Carcinoma *

Jordi Bruix, Morris Sherman · Hepatology · 2005 · 5.9K citations · Full text

Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference

Jordi Bruix, Morris Sherman, Josep M. Llovet et al. · Journal of Hepatology · 2001 · 4.1K citations

, , +10

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

Roopinder Gillmore, Sam Stuart, Amy A. Kirkwood et al. · Journal of Hepatology · 2011 · 322 citations

, , +10

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

Julien Edeline, Éveline Boucher, Yan Rolland et al. · Cancer · 2011 · 271 citations · Full text